INSIGHTS
Home 9 All Posts 9 Industry News 9 Are Direct-to-Patient Access Models the Future of Pharma?
Team Archbow
  •  October 22

Are Direct-to-Patient Access Models the Future of Pharma?

Archbow discusses the growing potential to sell directly to patients via a cash model.

Are Direct-to-Patient Access Models the Future of Pharma?

In January, Eli Lilly launched LillyDirect, a website offering access to telehealth consultations and direct home delivery of certain drugs to treat diabetes, weight loss, and migraines. In Archbow Consulting’s blog post, we discussed the growing potential to sell directly to patients via a cash model.

Meanwhile, Pfizer recently launched a similar direct-to-consumer digital platform, PfizerForAll, which aims to simplify access to healthcare. PfizerForAll helps to streamline necessary health actions, fill prescriptions, and find potential savings on Pfizer medicines. As this new model gains popularity in the market and gross-to-net pressure continues to mount, we should expect additional manufacturers to introduce these direct-to-patient models.

 

Archbow’s recommendations for manufacturers considering a direct-to-patient model are as relevant today as they were nearly a year ago. The following types of organizations may benefit the most from this strategic model:

 

  • Large organizations with an extensive portfolio of drugs
  • Small organizations that may be forced to engage significant stakeholders (Wholesalers, PBMs, Retail Chains, etc.) at non-sustainable rates to secure commercial success
  • Any company with a pharmacy benefit product(s) that PBMs/Payers are closely monitoring and tightly managing

    If you are considering a direct-to-patient model, Archbow can help. We have the right advisors with decades of commercial planning experience to improve your program design efforts, and we have recently supported similar initiatives with multiple clients.

    Learn more about Team Archbow and the methodology that matters most to successful programs. Contact us today for assistance with your strategic and tactical patient support needs. Our team works seamlessly to align even the most complicated patient, product, and reimbursement journeys.

    For additional insights on this topic, you may also enjoy the following:

    Archbow Consulting helps pharmaceutical and biotech companies in the USA and Europe design, build, and optimize product distribution and patient access strategies. Archbow was founded by industry veterans to meet a need in the marketplace for consulting options that offer diverse real-world experience, are able to leverage deep connections across the industry, and can also provide actionable strategic guidance. We invite you to learn more about our team, services, and clients’ success, and connect with us via email, LinkedIn or subscribing to this blog which you can do below.
    Share in
    Recent Posts
    Key Takeaways from NASP 2024

    Key Takeaways from NASP 2024

    The 2024 National Association of Specialty Pharmacy (NASP) conference showcased a landscape of rapid innovation and evolving industry trends.

    SUBSCRIBE

    Subscribe to receive news and updates from Archbow Consulting